CALL - SPRINTER OPEN END - BIOGEN IDEC | Market Closed - Deutsche Boerse AG 11:14:10 22/05/2024 pm IST | ||
| 3.51 EUR | +0.29% |
|
| Current month | +29.52% | ||
| 1 month | +380.82% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 22/24/22 | 3.51 | +0.29% |
| 21/24/21 | 3.5 | -14.00% |
| 20/24/20 | 4.07 | +7.39% |
| 17/24/17 | 3.79 | -1.04% |
| 16/24/16 | 3.83 | -13.35% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 11:14 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VX7HCZ |
| ISIN | DE000VX7HCZ8 |
| Date issued | 22/02/2022 |
| Strike | 190.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14 € |
|---|---|
| Lowest since issue | 0.23 € |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
225.2
USD
Average target price
287.3
USD
Spread / Average Target
+27.57%
- Stock Market
- Certificates
- Certificat
